MannKind Corporation

MannKind Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic products and devices. The company's mission is to transform chronic disease care through patient-centric solutions, addressing significant unmet medical needs primarily in cardiometabolic and orphan lung diseases. MannKind's headquarters are located in Danbury, Connecticut, USA.

MannKind leverages its proprietary Technosphere® drug-delivery platform, which enables the rapid absorption of drugs through pulmonary administration. Key commercialized products include Afrezza®, a rapid-acting inhaled insulin for adults with diabetes, and V-Go®, an all-in-one insulin delivery patch. The company also markets FUROSCIX® (furosemide injection) for edema associated with chronic heart failure and chronic kidney disease through its wholly-owned subsidiary, scPharmaceuticals, and Tyvaso DPI® (treprostinil inhalation powder) for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, marketed by United Therapeutics.

Under the leadership of CEO Michael Castagna, PharmD, MannKind continues to advance its pipeline and market presence. Recent notable developments in 2026 include the FDA approval of an updated Afrezza label providing starting dose guidance, the settlement of convertible senior notes, and the enrollment of the first patient in the INHALE-1ST Pediatric Study for Afrezza in newly-diagnosed Type 1 Diabetes. The company reported fourth-quarter 2025 revenue of $112 million, a 46% increase year-over-year, and anticipates further regulatory milestones with upcoming FDA PDUFA dates for Afrezza pediatric on May 29, 2026, and Furoscix ReadyFlow on July 26, 2026.